4-nitro-3-(tetrahydrofuran-3-yloxy)-benzamide 在
钯乙醇 、 氮气 作用下,
以
乙醇 为溶剂,
反应 18.0h,
以to give the title compound as a white solid (4.22 g, 18.9 mmol, 100% corrected)的产率得到4-amino-3-(tetrahydrofuran-3-yloxy)-benzamide
参考文献:
名称:
Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
申请人:Aicher Babette
公开号:US20100056548A1
公开(公告)日:2010-03-04
The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
申请人:DeveloGen Aktiengesellschaft
公开号:EP2004656A1
公开(公告)日:2008-12-24
THIENOPYRIMIDINES HAVING MNK1 /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
申请人:Boehringer Ingelheim International GmbH
公开号:EP2004656B1
公开(公告)日:2013-07-10
US8633201B2
申请人:——
公开号:US8633201B2
公开(公告)日:2014-01-21
[EN] THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] THIÉNOPYRIMIDINES AYANT UNE ACTIVITÉ INHIBITRICE MNK1/MNK2 UTILISÉES DANS DES COMPOSITIONS PHARMACEUTIQUES
申请人:DEVELOGEN AG
公开号:WO2007115822A1
公开(公告)日:2007-10-18
[EN] The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. [FR] La présente invention concerne de nouvelles compositions pharmaceutiques contenant des composés de thiénopyrimidine. De plus, la présente invention concerne l'utilisation des composés de thiénopyrimidine pour la production de compositions pharmaceutiques destinées à prévenir et/ou à traiter des maladies susceptibles d'être influencées par l'inhibition de l'activité kinase de Mnk1 et/ou Mnk2 (Mnk2a ou Mnk2b) et/ou de variants desdites protéines kinases.